22507Optimizing the Management of Transthyretin Amyloid Cardiomyopathy in Patients with Heart Failure

In this symposium, three experts in ATTRCM (Dr. Mathew Maurer, Dr. Sarah Cuddy, and Dr. Melissa Lyle) will explain best practices for identifying and diagnosing ATTR-CM in patients with concomitant HF, describe the evidence for current ATTR-CM therapies and, through case presentation, discuss practical considerations in management.

Around 50% of patients experience HF symptoms/signs in the presence of a
preserved left ventricular ejection fraction, and half of these patients have increased
left ventricular wall thickness. Transthyretin amyloid cardiomyopathy (ATTR-CM), a
restrictive cardiomyopathy resulting from the deposition of amyloid fibrils in the
interstitial space of the heart muscle, commonly fits these characteristics. Having been
considered a rare disease in the past, ATTR-CM has been increasingly identified as a
much more frequent cause of HF than previously thought; ATTR-CM accounts for 6%
to 16% of older patients presenting with heart failure and increased left ventricular (LV)
wall thickness. Transthyretin amyloid cardiomyopathy is a progressive and fatal
condition if not diagnosed promptly. Disease-modifying treatments are now available,
and others are currently in development. However, the condition remains
misdiagnosed and underdiagnosed since awareness of the disease among clinicians
and in the community is less than optimal. In this symposium, three experts in ATTRCM
(Dr. Mathew Maurer, Dr. Sarah Cuddy, and Dr. Melissa Lyle) will explain best
practices for identifying and diagnosing ATTR-CM in patients with concomitant HF,
describe the evidence for current ATTR-CM therapies and, through case presentation,
discuss practical considerations in management.

Login to your Account